Pfizer introduced PfizerForAll, a user-friendly digital platform designed to make access to healthcare and managing health and wellness more seamless for people across the U.S. The new, end-to-end experience will support the millions of Americans affected annually by common illnesses like migraine, COVID-19 or flu, and those seeking to protect themselves with adult vaccinations. By bringing together critical resources and services into a single destination, PfizerForAll helps individuals and their families cut down on the time and steps needed to take important health actions like getting care, filling prescriptions, and finding potential savings on Pfizer medicines.
Pfizer is working within the existing U.S. healthcare system and partnering with a growing network of healthcare organizations to launch and develop PfizerForAll. Patients will be able to use existing insurance and pharmacy programs and will also benefit from new direct services from partners including UpScriptHealth , Alto Pharmacy and Instacart – Read More.
Recently, the U.S. Food and Drug Administration approved and granted emergency use authorization (EUA) for updated mRNA COVID-19 vaccines (2024-2025 formula) to include a...
Flexible coils for magnetic resonance imaging are being designed to search for breast cancer faster and with less disadvantages. In a project funded by the Austrian Scien...
Pfizer introduced PfizerForAll, a user-friendly digital platform designed to make access to healthcare and managing health and wellness more seamless for people across th...
From the high tech to the medical sector, AI is showing all its resources, opening the doors to many global innovations. In a rapidly changing world, modern society is...
Stryker announced the launch of LIFEPAK 35 monitor/defibrillator, the latest product in the monitor/defibrillator space, offering advanced technology and built on an intu...
Henry Schein UK announced today the expansion of the company’s CRITERION® brand, which includes gloves as well as soon a head-to-toe line of personal protective equipment...
New York- Pfizer Inc. has announced promising topline data from its Phase 2b clinical trial (NCT04707313) evaluating the oral Glucagon-like peptide-1 receptor agonist (GL...
A virtual marketplace leading your business into the future
